Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Coya Therapeutics has received a consensus recommendation of "Moderate Buy" from six research firms, with five buy ratings and one sell rating among them.
• The company's stock price target varies, with estimates ranging from $14.00 to $18.00 from different research analysts.
• Coya Therapeutics' stock is currently down 9.7% and has reported a loss of $0.36 earnings per share in its recent quarterly earnings results.

Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $16.20.

A number of research firms have recently issued reports on COYA. Weiss Ratings reissued a "sell (d-)" rating on shares of Coya Therapeutics in a report on Friday. Lake Street Capital started coverage on shares of Coya Therapeutics in a research note on Wednesday, July 9th. They set a "buy" rating and a $16.00 price target on the stock. D. Boral Capital reiterated a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, September 29th. Chardan Capital reiterated a "buy" rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Wednesday, September 17th. Finally, BTIG Research reiterated a "buy" rating and set a $15.00 target price on shares of Coya Therapeutics in a research report on Tuesday, September 30th.

Institutional Trading of Coya Therapeutics

Large investors have recently modified their holdings of the business. CM Management LLC boosted its stake in shares of Coya Therapeutics by 25.0% during the first quarter. CM Management LLC now owns 200,000 shares of the company's stock valued at $1,294,000 after acquiring an additional 40,000 shares during the last quarter. Dauntless Investment Group LLC acquired a new stake in shares of Coya Therapeutics during the first quarter valued at $1,083,000. Jane Street Group LLC boosted its stake in shares of Coya Therapeutics by 101.7% during the first quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock valued at $169,000 after acquiring an additional 13,176 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Coya Therapeutics during the 2nd quarter worth about $119,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Coya Therapeutics during the 1st quarter worth about $65,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Stock Down 9.7%

Coya Therapeutics stock opened at $6.30 on Friday. The firm has a market cap of $105.40 million, a PE ratio of -5.08 and a beta of 0.19. Coya Therapeutics has a 52-week low of $4.65 and a 52-week high of $10.24. The company's 50 day moving average is $6.20 and its two-hundred day moving average is $6.00.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.14). The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.78 million. On average, equities research analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.